The Food and Drug Administration (FDA) on Friday (May 7) has approved the Certificate of Product Registration (CPR) of a pharmaceutical company for the locally manufactured ivermectin as an anti-nematode.
According to FDA Director General Eric Domingo, the department granted a CPR to local pharmaceutical company Lloyd Laboratories Inc., following the latter’s submission of data to “support quality and stability” of the locally manufactured ivermectin as an anti-nematode drug. Nematodes are parasitic roundworms.
“Lloyd Laboratories applied for a CPR for locally manufactured ivermectin as an anti-nematode drug and it was granted after they submitted data to support quality and stability of the product.”
However, the FDA Chief clarified that the approved CPR for ivermectin is only as an anti-nematode drug, it still cannot be used as treatment for COVID-19. It will also be made available through only prescription.
Report from Mark Fetalco/NGS-rir
